Response by Pleva et al to Letter Regarding Article, "Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study"
| Autoři | |
|---|---|
| Rok publikování | 2016 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Circulation: Cardiovascular Interventions |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.1161/CIRCINTERVENTIONS.116.004304 |
| Obor | Kardiovaskulární nemoci včetně kardiochirurgie |
| Klíčová slova | coronary restenosis; diabetes mellitus; drug-eluting stents; paclitaxel; stents |
| Popis | We read with great interest the letter by Alfonso et al with comments to our study.1 We know the interesting results of the RIBS V study (Restenosis Intra-Stent of Bare-Metal Stents: Paclitaxel-Eluting Balloon vs. Everolimus-Eluting Stent). Contrary to RIBS V, we used everolimus-eluting stents (EES) with platinum-chromium metallic platform and a different primary end point, 12-month late lumen loss (LLL) in our study. |